Filing Summary
Business Context and Reporting Period
This Form 6-K was filed by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, for June 2023. The filing concerns the company’s notice of meeting and proxy card for its ordinary shareholders’ meeting scheduled for June 30, 2023.
The filing identifies the registrant as NLS Pharmaceutics Ltd.; the provided request metadata refers to Newcelx Ltd., which does not match the filing text.
Meeting and Voting Matters
- The meeting is scheduled for June 30, 2023, including any postponement or adjournment.
- Only shareholders of record holding common shares at the close of business on June 1, 2023, are entitled to vote.
- Exhibit 99.1 contains the notice of meeting and proxy card.
- The filing is incorporated by reference into the company’s specified Form F-3 registration statements.
Financial Information
The filing does not provide financial statements, revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating metrics.
Material Changes, Outlook, and Risks
The filing text does not describe material changes from a prior period, management outlook, contingencies, unusual items, or specific risk factors. Its primary purpose is to furnish shareholder-meeting materials.
Important Facts to Verify
- Confirm the registrant identity, because the filing names NLS Pharmaceutics Ltd. rather than Newcelx Ltd.
- Review Exhibit 99.1 for the meeting agenda, proposed resolutions, proxy procedures, and voting recommendations.
- Verify the June 1, 2023 record date and June 30, 2023 meeting date.
- Consult other SEC filings for financial performance, liquidity, financing, and risk information not included in this Form 6-K.